RESEARCH PLATFORM
FOR DRUG DEVELOPMENT

FIRST-IN-HUMAN DATA GENERATION

Our platform uses real ex vivo donor-derived adipose tissue models to mimic pathological conditions related to obesity and chronic metabolic diseases and generate first-in-human data to increase clinical success of novel drug candidates and pharmacological approaches.
Learn More

For a paradigm shift in obesity research

Obesity is associated with chronic metabolic diseases, such as MASH, steatosis, type-2 diabetes and cardiovascular diseases. Despite the emergence of novel effective treatments in recent years, millions of people with obesity remain with no tailored therapeutic solution, in particular patients who are poorly responding to anti-obesity drugs.

In obesity, the balance between white adipose tissue (the ‘bad’ fat) and brown adipose tissue (the ‘good’ fat) is altered, with white adipose tissue accumulating and becoming dysfunctional, while brown adipose tissue disappears or is impaired. Brown adipose tissue is known for its energy expenditure capabilities and to regulate metabolism by secreting specific factors preventing chronic metabolic diseases.

Stimulating or restoring these natural beneficial properties of adipose tissue through 'browning' of white adipose tissue can have a profound impact on obesity management and pave the way for a comprehensive therapeutic approach for obesity.

A Breakthrough Technology for Chronic Metabolic Disorders and Obesity

ObAdEx is our breakthrough technology that overcomes the barrier of ex vivo culture and production of a viable and metabolically active adipose tissue

Our technology allows us to mimic ex vivo physio-pathological conditions of human adipose tissue associated to obesity and chronic metabolic diseases for a fine understanding of mechanisms of actions of lead drug candidates for these indications.

ObAdEx adipose tissue models are derived from donors and retain the donors' browning capacity, thus being a powerful tool to generate first-in-human ex vivo data for drug development targeting energy expenditure. Activation of energy expenditure potential in patients with obesity might indeed restore metabolic homeostasis, preventing and treating chronic metabolic diseases.

ObAdEx has received Deeptech label by BpiFrance and is being developed in collaboration with SATT Sud-Est, CNRS, Nice University Hospital and Côte d’Azur University/Idex.

2023

Early
development

2024

Process scale-up
& industrial adaptation

2025

Non-regulatory
preclinical

2026

Clinical batch &
Bridging studies

2027

First-in-patient
DARK CIRCLES,
PUFFY EYES, EYE BAGS
ExAdEx vascularized 3D adult organoid models obtained from freshly isolated subcutaneous adipose tissue allow to support claims related to vasoconstriction, vasodilation, stimulation of lymphatic network and drainage
Vascular/Lymphatic
ANTI-AGING, SKIN HEALTH,
TISSUE REGENERATION
ExAdEx donor-derived 3D inflammatory and fibrotic tissue models mimic complex skin interactions, allowing for claim substantiation of tissue remodeling, anti-stress, regenerative and anti-aging products
Physio-Pathological
FAT BURNING,
METABOLIC ACTIVITY
ExAdEx 3D real fat tissue models are the only clinically relevant ex vivo models with physiological fat burning and browning capacity, supporting claims targeting weight management, cellulite and metabolic well-being
Fat burning

GET IN TOUCH

We are happy to answer all your questions, discuss your needs and provide you with tailored solutions.
Please contact us and we will answer as soon as possible.
EXADEX-INNOV
Bioincubateur
Institut de Biologie Valrose
28 Avenue de Valombrose
06100 Nice (FRANCE)

Legal mentions

Copyright © 2022 ExAdEx-Innov All rights reserved

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management